Mass-Spec Dx Makers Should Look To FDA's Multiplex, Multivariate Approach For Regulatory Tips
This article was originally published in The Gray Sheet
Executive Summary
As FDA develops a framework for liquid chromatography-mass spectrometry diagnostics, the agency's previously circulated policies on multiplex test instrument systems and in vitro diagnostic multivariate index assays offer hints as to what LC-MS companies can expect.
You may also be interested in...
FDA Addresses Pre-Submission Meetings In Draft Guidance
With the draft guidelines, FDA takes a step toward fulfilling one of its commitments under the reauthorized device user fee program to establish a more structured process for pre-submission meetings with industry.
Agendia Boasts Expanded Clearance, Reimbursement For Breast Cancer Test
Gene expression test maker Agendia will ramp up its U.S. marketing efforts after gaining expanded FDA clearance and Medicare coverage for its flagship MammaPrint breast cancer recurrence test
FDA Takes Second Stab At Multivariate Diagnostic Oversight Guidelines
FDA cautiously moved ahead with its controversial plan to actively regulate certain laboratory-developed tests with the release of a revised 1draft guidance document July 24